Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
For the first time since opening an internal probe into clinical trials run in Japan for its Diovan blood pressure drug, Novartis has acknowledged signs of wrongdoing. In a statement on its web site, the drugmaker has admitted that two employees had varying levels of involvement in clinical trials that were initiated by investigators but were supposed to have been independent. “Our current understanding is that one of our former employees had varying levels of involvement in five investigator-initiated (Diovan) trials in Japan. In addition, a second former employee, who reported to the first former employee, had involvement which was limited to one of these trials,” the drugmaker writes.
Help employers find you! Check out all the jobs and post your resume.
